Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety and Efficacy of QH101 in Patients With Relapsed/Refractory Acute Myeloid Leukemia(R/R AML) and Relapsed/Refractory Myelodysplastic Syndromes(R/R MDS)

NCT07131085 is registered in ClinicalTrials.gov with Anhui Provincial Hospital as lead sponsor.

NCT NCT07131085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07131085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety and Efficacy of QH101 in Patients With Relapsed/Refractory Acute Myeloid Leukemia(R/R AML) and Relapsed/Refractory Myelodysplastic Syndromes(R/R MDS)
Lead sponsor
Anhui Provincial Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 15, 2025
Completion date
December 31, 2027
Enrollment
9 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aml, mds